NCT02810756View on ClinicalTrials.gov

Study With Improved Solubility Pazopanib

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 15, 2016

Primary Completion Date

August 28, 2017

Study Completion Date

August 28, 2017

Conditions
Pharmacokinetics of Pazopanib
Interventions
DRUG

New Pazopanib formulation

Trial Locations (1)

1066 CX

Netherlands Cancer Institute, Amsterdam

All Listed Sponsors
lead

The Netherlands Cancer Institute

OTHER

NCT02810756 - Study With Improved Solubility Pazopanib | Biotech Hunter | Biotech Hunter